| Today's Big NewsJun 8, 2023 |
|
Montgomery County, MD, is a thriving innovation hub for the life sciences industry. Be Next and learn how companies are making their mark in the immunology capital next to the nation’s capital. Learn more. 
|
|
| By James Waldron Astellas has been haunted by patient deaths in a previous trial for a tricky neuromuscular condition, but that hasn’t stopped the Japanese Big Pharma from seeking out another gene therapy to target the same indication. |
|
|
|
| San Diego, CA |  |
|
|
By Nick Paul Taylor Arvinas is pushing ahead with plans to expand development of its prostate cancer prospect ARV-766 into earlier-line settings. The biotech linked the protein degrader to declines in the PSA biomarker and partial responses in a phase 1/2 trial, providing early hints of its ability to overcome resistance mechanisms. |
By Nick Paul Taylor GreenLight Biosciences is pushing ahead with plans to shrink its headcount. Shortly after the biotech put out news of a 51% reduction of its team, a notice in Massachusetts revealed 96 of the layoffs will happen at facilities in the state next month. |
By Annalee Armstrong,Gabrielle Masson,Max Bayer We had hoped that our Layoff Tracker would stay retired for a while, but 2023 is starting to look a lot like our old friend 2022 when it comes to layoffs in biotech. |
By Gabrielle Masson,Max Bayer,Annalee Armstrong Alongside the new year, we've launched a new Fierce Biotech Fundraising Tracker to keep the pulse on the industry's financing. |
By Annalee Armstrong,Max Bayer,Gabrielle Masson Fierce Biotech's M&A Tracker, your one-stop shop for dealmaking in the biopharma universe. |
By Kevin Dunleavy Legend Biotech and Johnson & Johnson have filed with the FDA for expanded use of Carvykti. After gaining approval 16 months ago for the CAR-T to treat multiple myeloma patients following four or more lines of therapy, the companies hope to get the U.S. regulator to sign off on its use at an earlier stage of treatment. |
By Eric Sagonowsky As Alzheimer's partners Eisai and Biogen lay the groundwork for a wider launch of Leqembi, their efforts center on winning a full FDA approval. On Wednesday, that vision came into better focus as the FDA released a document showing how the agency views the drug. |
By Andrea Park People ages 18 and up with ADHD can now access a version of Akili's Endeavor video game-based digital therapeutic without requiring a prescription. |
By Zoey Becker The National Comprehensive Cancer Network's recent survey shows that nearly all of the treatment centers it polled are facing a carboplatin shortage. Meanwhile, 70% of them reported a cisplatin shortage. The organization polled 27 treatment centers. |
By Annie Burky Syntax Health launched a new platform designed to smooth out the value-based care contracting process using analytics, infrastructure and a collaborative virtual workspace. The solution allows payers and providers to model contract scenarios with increased transparency while foreseeing performance trends. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we discuss the need to democratize access to medications like emergency contraception, plus Elizabeth Holmes, the state of Alzheimer's research, and the rest of the week's headlines. |
|
|---|
|
|
|
October 16-18, 2023 | Boston, MA Hear from leading experts as they share their experiences and insights covering drug development from the earliest stage of research to FDA approval. Save $500 when you Register before June 19th! 
|
|
Whitepaper Autoantibody screening is promising for early cancer detection with the potential to improve the whole treatment decision tree, providing a less invasive, powerful approach. Sponsored by: Sengenics |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
eBook See how clinical trial sponsors can build stronger strategies to address challenges across the patient enrollment funnel, starting with four necessary steps. Sponsored by: OneStudyTeam |
Whitepaper This paper outlines various market archetypes and key considerations leaders must address when prioritizing new potential markets for gene therapies. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Whitepaper ChatGPT shows promise in drug discovery for information extraction, scientific text authoring, hypothesis prediction, and chemical entity prediction. This whitepaper explores its potential to streamline research, delving into its technology, applications, and limitations. Sponsored by: Elucidata Corp., Cloud SAAS in Life Sciences R&D |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
| July 18-19, 2023 | Jersey City, NJ |
|
|
| |
|
